Opioid antagonists differ according to negative intrinsic efficacy in a mouse model of acute dependence

British Journal of Pharmacology

Volumn 145, Issue 7, 2005, Pages 975-983

  Walker, Ellen A ^a   Sterious, Steven N ^a  

^a TEMPLE UNIVERSITY SCHOOL OF PHARMACY   (United States)

Author keywords

Acute dependence; Diprenorphine; Intrinsic efficacy; Inverse agonist; Mice; Nalorphine; Naloxonazine; Naloxone; Naltrexone; Opioid withdrawal; Withdrawal jumping

Indexed keywords

DIPRENORPHINE; MORPHINE; NALORPHINE; NALOXONAZINE; NALTREXONE; OPIATE ANTAGONIST;

ANIMAL BEHAVIOR; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; DRUG DEPENDENCE; DRUG EFFICACY; DRUG INHIBITION; DRUG WITHDRAWAL; JUMPING; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; TREMOR; WEIGHT REDUCTION;

ANIMALS; BEHAVIOR, ANIMAL; BODY WEIGHT; BRAIN; DIPRENORPHINE; DOSE-RESPONSE RELATIONSHIP, DRUG; MALE; MICE; MORPHINE; MORPHINE DEPENDENCE; NALOXONE; NALTREXONE; NARCOTIC ANTAGONISTS; SUBSTANCE WITHDRAWAL SYNDROME; TREMOR;

EID: 23744466581     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0706247     Document Type: Article

References (58)

1. ADAMS, J.U., GELLER, E.B. & ADLER, M.W. (1994). Receptor selectivity of icv morphine in the rat cold water tail-flick test. Drug Al. Depend., 35, 197-202.
2. 2 and the protein kinase inhibitors H7 and H8 on acute morphine dependence and antinociceptive tolerance in mice. J. Pharmacol. Exp. Ther., 277, 484-490.
3. BLÄSIG, J., HERZ, A., REINHOLD, K. & ZIEGLGANSBERGER, S. (1973). Development of physical dependence on morphine in respect to time and dosage and quantification of the precipitated withdrawal syndrome in rats. Psychopharmacologia, 33, 19-38.
4. BLÄSIG, J., HÖLLT, V., HERZ, A. & PASCHELKE, G. (1976). Comparison of withdrawal precipitating properties of various morphine antagonists and partial agonists in relation to their stereospecific binding to brain homogenates. Psychopharmacologia, 46, 41-51.
5. BRILLET, K., KIEFFER, B.L. & MOSSATTE, D. (2003). Enhanced spontaneous activity of the mu opioid receptor by cysteine mutations: characterization of a tool for inverse agonist screening. BMC Pharmacol., 3, 1-12.
6. BROSETA, I., RODRIGUEZ-ARIAS, M., STINUS, L. & MINARRO, J. (2002). Ethological analysis of morphine withdrawal with different dependence programs in male mice. Prog. Neuropsychopharmacol. Biol. Psychiatry, 2, 335-347.
7. BURFORD, N.T., WANG, D.X. & SADEE, W. (2000). G-protein coupling of mu-opioid receptors (OP3) elevated basal-signaling activity. Biochem. J., 348, 531-537.
8. CHENEY, D.L., JUDSON, B.A. & GOLDSTEIN, A. (1972). Failure of an opiate to protect mice against naloxone precipitated withdrawal. J. Pharmacol. Exp. Ther., 182, 189-193.
9. COSTA, T. & HERZ, A. (1989). Antagonists with negative intrinsic activity at delta opioid receptors coupled to GTP-binding proteins. Proc. Natl. Acad. Sci. U.S.A., 86, 7321-7325.
10. COOK, C.D., BARRET, A.C., ROACH, E.L., BOWMAN, J.R. & PICKER, M.J. (2000). Sex-related differences in the antinociceptive effects of opioids: importance of rat genotype, nociceptive stimulus intensity, and efficacy at the mu opioid receptor. Psychopharmacology, 150, 430-442.
11. COWAN, A. (1976). Use of the mouse-jumping test for estimating antagonistic potencies of morphine antagonists. J. Pharm. Pharmacol., 28, 177-182.
12. FATHY, D.B., LEEB, T., MATHIS, S.A. & LEEB-LUNDBERG, L.M.F. (1999). Spontaneous human B2 bradykinin receptor activity determines the action of partial agonists as agonists or inverse agonists - effect of basal desensitization. J. Biol. Chem., 274, 29603-29606.
13. FERNANDEZ-ESPEJO, E., CADOR, M. & STINUS, L. (1995). Ethopharmacological analysis of naloxone-precipitated morphine withdrawal syndrome in rats: a newly-developed 'etho-score'. Psychopharmacology, 122, 122-130.
14. FRANCE, C.P. & MORSE, W.H. (1989). Pharmacological characterization of supersensitivity to naltrexone in squirrel monkeys. J. Pharmacol. Exp. Ther., 250, 928-936.
15. GATCH, M.B., LIGUORI, A., NEGUS, S.S., MELLO, N.K., BERGMAN, J. & LIGUORI, T. (1996). Naloxonazine antagonism of levorphanol-induced antinociception and respiratory depression in rhesus monkeys. Eur. J. Pharmacol., 298, 31-36.
16. GEARY, W.A. & WOOTEN, G.F. (1985). Regional saturation studies of 3H-naloxone binding in the naïve, dependent and withdrawal states. Brain Res., 360, 214-223.
17. GHARAGOZLOU, P., DEMIRCI, H., CLARK, J.D. & LAMEH, J. (2003). Activity of opioid ligands in cells expressing cloned μ-opioid receptors. BMC Pharmacol., http://www.biomedcentral.com/1471-2210/3/1.
18. GILLAN, M.G.C. & KOSTERLITZ, H.W. (1982). Spectrum of the μ-, δ-and κ-binding sites in homogenates of rat brain. Br. J. Pharmacol., 77, 461-469.
19. GOLDSTEIN, A. & NAIDU, A. (1989). Multiple opioid receptors: ligand selectivity profiles and binding site signatures. Mol. Pharmacol., 36, 265-272.
20. GULYA, K., KRIVAN, M., NYOLCZAS, N., SARNYAI, Z. & KOVACS, G.L. (1988). Central effects of the potent and highly selective μ opioid antagonist D-Phe-Cys-Tyr-D-Trp-Orn-Thr-Pen-Thr-NH2 (CTOP) in mice. Eur. J. Pharmacol., 150, 355-360.
21. HAHN, E.F., CARROLL-BUATTI, M. & PASTERNAK, G.W. (1982). Irreversible opiate agonists and antagonists: the 14-hydroxydihydromorphinone azines. J. Neurosci., 2, 572-576.
22. HEYMAN, J.S., WILLIAMS, C.L., BURKS, T.F., MOSBERG, H.I. & PORRECA, F. (1988). Dissociation of opioid antinociception and central gastrointestinal propulsion in the mouse: studies with naloxonazine. J. Pharmacol. Exp. Ther., 245, 238-243.
23. HUIDOBRO, F. & MAGGIOLO, C. (1965). Studies on morphine. IX. On the intensity of the abstinence syndrome to morphine induced by daily injections of nalorphine in white mice. Arch. Int. Pharmacodyn. Ther., 158, 97-112.
24. JOHNSON, N. & PASTERNAK, G.W. (1984). Binding of [3H]naloxonazine to rat brain membranes. Mol. Pharmacol., 26, 477-483.
25. KENAKIN, T. (2004). Efficacy as a vector: the relative prevalence and paucity of inverse agonism. Mol. Pharmacol., 65, 2-11.
26. KOSERSKY, D.S., HARRIS, R.A. & HARRIS, L.S. (1974). Naloxone-precipitated jumping activity in mice following the acute administration of morphine. Eur. J. Pharmacol., 26, 122-124.
27. KRAMER, T.H., SHOOK, J.E., KAZMIERSKI, W., AYRES, E.A., WIRE, W.S., HRUBY, V.J. & BURKS, T.F. (1989). Novel peptidic mu opioid antagonists: pharmacologic characterization in vitro and in vivo. J. Pharmacol. Exp. Ther., 249, 544-549.
28. LEE, K.O., AKIL, H., WOODS, J.H. & TRAYNOR, J.R. (1999). Differential binding properties of oripavines at cloned μ- and δ-opioid receptors. Eur. J. Pharmacol., 378, 323-330.
29. LING, G.S.F., SIMANTOV, R., CLARK, J.A. & PASTERNAK, G.W. (1985a). Naloxonazine actions in vivo. Eur. J. Pharmacol., 129, 133-137.
30. LING, G.S.F., SPIEGEL, K., LOCKHART, S.H. & PASTERNAK, G.W. (1985b). Separation of opioid analgesia from respiratory depression: evidence for different receptor mechanisms. J. Pharmacol. Exp. Ther., 232, 149-155.
31. LINSEMAN, M.A. (1977). Naloxone-precipitated withdrawal as a function of the morphine-naloxone interval. Psychopharmacology, 54, 159-164.
32. LIU, J.G. & PRATHER, P.L. (2001). Chronic exposure to m-opioid agonists produces constitutive activation of m-opioid receptors in direct proportion to the efficacy of agonist used for pretreatment. Mol. Pharmacol., 60, 53-62.
33. MALDONADO, R., MICO, J.A., VALVERDE, O., SAAVEDRA, M.C., LEONSEGUI, I. & GIBERT-RAHOLA, J. (1991). Influence of different benzodiazepines on the experimental morphine abstinence syndrome. Psychopharmacology, 105, 197-203.
34. MALDONADO, R., NEGUS, S.S. & KOOB, G. (1992). Precipitation of morphine withdrawal syndrome in rats by administration of mu-, delta-, and kappa-selective opioid antagonists. Neuropharmacology, 31, 1231-1241.
35. MANSOUR, A. & WATSON, S.J. (1993). Anatomical distribution of opioid receptors in mammalians: and overview. In: Opioids, ed. Herz A., pp.. Berlin: Springer-Verlag, pp 79-105.
36. MIYAMOTO, Y. & TAKEMORI, A.E. (1993). Inhibition of naloxone-precipitated withdrawal jumping by I.c.v. and i.t. administration of saline in morphine-dependent mice. Life Sci., 52, 1129-1134.
37. MUNDEY, M.K., ALI, A., MASON, R. & WILSON, V.G. (2000). Pharmacological examination of contractile response of the guinea-pig isolated ileum produced by m-opioid receptor antagonists in the presence of, and following exposure to, morphine. Br. J. Pharmacol., 131, 893-902.
38. PORTER, S.J., SOMOGYI, A.A. & WHITE, J.M. (2002). In vivo and in vitro potency studies of 6-beta-naltrexol, the major human metabolite of naltrexone. Addict. Biol., 7, 219-225.
39. SHAW, J.S., ROURKE, J.D. & BURNS, K.M. (1988). Differential sensitivity of antinociceptive tests to opioid agonists and partial agonists. Br. J. Pharmacol., 95, 578-584.
40. SMITS, S.E. (1975). Quantification of physical dependence in mice by naloxone-precipitated jumping after a single dose of morphine. Res. Commun. Chem. Path. Pharmacol., 10, 651-661.
41. SOFUOGLU, M., SATO, J. & TAKEMORI, A.E. (1990). Maintenance of morphine dependence by naloxone in acutely dependent mice. J. Pharmacol. Exp. Ther., 254, 841-846.
42. STERIOUS, S.N. & WALKER, E.A. (2003). Potency differences for D-Phe-Cys-Tyr-D-Trp-Arg-Thr-Pen-Thr-NH2 as an antagonist of peptide and alkaloid μ-agonists in an antinociception assay. J. Pharmacol. Exp. Ther., 304, 301-309.
43. s coupling. J. Pharmacol. Exp. Ther., 310, 256-262.
44. TOLL, L. (1992). Comparison of mu opioid receptor binding on intact neuroblastoma cells with guinea pig brain and neuroblastoma cell membranes. J. Pharmacol. Exp. Ther., 260, 9-15.
45. VALVERDE, O., MICO, J.A., MALDONADO, R. & GIBERT-RAHOLA, J. (1992). Changes in benzodiazepine-receptor activity modify morphine withdrawal syndrome in mice. Drug Alcohol Depend., 80, 293-300.
46. WALKER, E.A., BUTELMAN, E.R., DECOSTA, B.R. & WOODS, J.H. (1993). Opioid thermal antinociception in rhesus monkeys: receptor mechanisms and temperature dependency. J. Pharmacol. Exp. Ther., 267, 280-286.
47. WALKER, E.A., PICKER, M.J. & DYKSTRA, L.A. (2001). Three-choice discrimination in pigeons is based on relative efficacy differences among opioids. Psychopharmacology, 155, 389-396.
48. WALKER, E.A., PICKER, M.J., GRANGER, A. & DYKSTRA, L.A. (2004). Effects of opioids in morphine-treated pigeons trained to discriminate among morphine, the low-efficacy agonist nalbuphine and saline. J. Pharmacol. Exp. Ther., 310, 150-158.
49. WANG, D., RAEHAL, K.M., BILSKY, E.J. & SADEE, W. (2001). Inverse agonists and neutral antagonists at μ opioid receptor (MOR): possible role of basal receptor signaling in narcotic dependence. J. Neurochem., 77, 1590-1600.
50. WANG, D., RAEHAL, K.M., LIN, E.T., LOWERY, J.J., KIEFFER, B.L., BILSKY, E.J. & SADEE, W. (2004). Basal signaling activity of μ-opioid receptor in mouse brain: role in narcotic dependence. J. Pharmacol. Exp. Ther., 308, 512-520.
51. WANG, D., SURRAT, C.R. & SADEE, W. (2000). Calmodulin regulation of basal and agonist-stimulated G protein coupling by the m-opioid receptor (OP3) in morphine-pretreated cells. J. Neurochem., 75, 763-771.
52. WANG, Z., BILSKY, E.J., PORRECA, F. & SADEE, W. (1994). Constitutive mu opioid receptor activation as a regulatory mechanism underlying narcotic tolerance and dependence. Life Sci., 54, PL339-PL350.
53. WANG, Z., BILSKPL, E.J., WANG, D., PORRECA, F. & SADEE, W. (1999). 3-Isobutyl-1-methylxanthine inhibits basal μ-opioid receptor phosphorylation and reverses acute morphine tolerance and dependence in mice. Eur. J. Pharmacol., 371, 1-9.
54. WAY, E.L., LOH, H.H. & SHEN, F.H. (1969). Simultaneous quantitative assessment of morphine tolerance and physical dependence. J. Pharmacol. Exp. Ther., 167, 1-8.
55. WILEY, J.N. & DOWNS, D.A. (1979). Naloxone-precipitated jumping in mice pretreated with acute injections of opioids. Life Sci., 25, 797-802.
56. YANG, Q. & LANIER, S.M. (1999). Influence of G protein type on agonist efficacy. Mol. Pharmacol., 56, 651-656.
57. YANO, I. & TAKEMORI, A.E. (1977). Inhibition by naloxone of tolerance and dependence in mice treated acutely and chronically with morphine. Res. Commun. Chem. Pathol. Pharmacol., 16, 721-734.
58. YOUNG, A.M., MASAKI, M.A. & GEULA, C. (1992). Discriminative stimulus effects of morphine: effects of training dose on agonist and antagonist effects of mu opioids. J. Pharmacol. Exp. Ther., 261, 246-257.